There are 315 resources available
Live closing remarks
Presenter: Giuseppe Curigliano
Session: Live closing remarks
Resources:
Webcast
3O - Spatial analysis of lymphocytes and fibroblasts identifies biological relevant patterns in estrogen receptor positive breast cancer
Presenter: Iris Nederlof
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
92O - Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
Presenter: Charles Powell
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
44O - Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE
Presenter: Masakazu Toi
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Live introduction
Presenter: Speaker not yet confirmed
Session: Adjuvant treatment early HER+ in breast cancer
Resources:
Webcast
Current standard approaches for early stage HER2+ disease
Presenter: Sara Hurvitz
Session: Adjuvant treatment early HER+ in breast cancer
Resources:
Slides
Webcast
The path ahead: De-escalating and escalating care for early stage HER2+ disease
Presenter: Sibylle Loibl
Session: Adjuvant treatment early HER+ in breast cancer
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: All Speakers
Session: Adjuvant treatment early HER+ in breast cancer
Resources:
Webcast
How low should we go? Treatment for stage I HER2+ disease
Presenter: Sara Tolaney
Session: Adjuvant treatment early HER+ in breast cancer
Resources:
Slides
Webcast
LBA2 - Impact of RNA expression signatures and tumor infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial.
Presenter: Monika Graeser
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast